Key Highlights
- Shares closed at A$199.38 on 18 November 2026, down 0.09% on the day and up approximately 10.72% over one year.
- Underlying NPATA was US$3.1 billion, down 2%, for the 12 months to 30 June 2026.
- The reported net loss after tax was US$2.6 billion, after restructuring costs and impairments.
- Cost savings of approximately US$176 million were achieved, ahead of the company's target.
CSL Limited (ASX:CSL) is a biotechnology company that develops and manufactures plasma-derived therapies and other biological medicines. Its shares closed at A$199.38 on 18 November 2026, down 0.09% for the session and up approximately 10.72% over the past year. The company released its FY26 results in August 2026, ahead of an investor briefing on 18 August 2026.
Latest Update
CSL reported underlying NPATA of US$3.1 billion for the 12 months to 30 June 2026, down 2%. After one-off restructuring costs and impairments, the company reported a net loss after tax of US$2.6 billion. Cash Flow from operations was US$3.5 billion. Pre-tax restructuring costs for the year were US$799 million.
The company said its transformation program achieved approximately US$176 million in cost savings, ahead of its target, and that the integration of Behring and Vifor commercial and medical affairs removed duplication. The final Dividend of US$1.62 per share was maintained, and the company continued its share buy-back. CSL also announced a strategic collaboration with the Dutch biotechnology company VarmX.
Company Background and Sector Context
CSL's Business centres on plasma-derived therapies, with newer products including ANDEMBRY and HEMGENIX. The release says that momentum is building behind these newer therapies, while plasma market Demand is described as remaining firm.
The plasma therapies sector depends on donor collection volumes, Manufacturing capacity and reimbursement decisions, and changes in those areas can affect product Supply and pricing.
CSL's plasma collection, manufacturing and distribution activities are central to its business, and the release notes the integration of the Behring and Vifor businesses. The company also entered a strategic collaboration with VarmX for a potential novel treatment to help restore blood coagulation. Its one-off pre-tax restructuring costs of US$799 million in the year relate to the transformation program, which the company said had simplified the organisation and reduced duplication.
Risks and Uncertainties
The reported net loss reflects restructuring costs and impairments, and the company has yet to return to growth in underlying earnings. Revenue fell 1% to US$15.8 billion during the year, and the company said it intends to invest in commercial capabilities to support future top-line growth.
Leadership is an open item in the release, which describes the chief executive role as interim. The timing of any permanent appointment and its effect on strategy remain uncertain.
What to Watch Ahead
Investors will watch the pace of return to sustainable growth, the delivery of the newer therapy launches and the continuation of the transformation program. Updates on the VarmX collaboration and any further restructuring will also be relevant.
Updates on the ANDEMBRY and HEMGENIX launches and on the outcome of the VarmX collaboration will be important markers. Investors may also watch the cost base as the transformation program moves into its next phase.
Taken together, the FY26 release shows a reset year, with lower underlying earnings, a substantial reported loss and cost savings ahead of target. The share price has risen over the past year, and progress on the newer therapies and the return to growth will be the next measures.






Please wait processing your request...